Abstract
In sum, the FTIs are signal transduction inhibitors that display promising clinical activity against a broad spectrum of malignancies. We are just beginning to explore and elucidate the mechanisms by which transformed cells respond to FTIs and the optimal settings in which they do so. The clinical trials that are currently in progress and under development will provide the critical foundations for defining the optimal roles of FTIs in patients with AML and other hematologic disorders. The correlative laboratory studies to define the mechanisms by which FTIs alter cellular metabolism and modulate the activities of specific signaling pathways in both normal and malignant marrow precursors are a pivotal part of this effort. What we learn about FTIs in the clinic and the laboratory will apply broadly to the effective and safe application of all signal transduction inhibitors.
Keywords: transduction pathways, farnesyl protein transferase, oncoproteins, Myelodysplasias, Phosphatidylinositol-3 Kinase
Current Molecular Medicine
Title: Targeting the Process of Farynesylation for Therapy of Hematologic Malignancies
Volume: 5 Issue: 7
Author(s): Judith E. Karp and Jeffrey E. Lancet
Affiliation:
Keywords: transduction pathways, farnesyl protein transferase, oncoproteins, Myelodysplasias, Phosphatidylinositol-3 Kinase
Abstract: In sum, the FTIs are signal transduction inhibitors that display promising clinical activity against a broad spectrum of malignancies. We are just beginning to explore and elucidate the mechanisms by which transformed cells respond to FTIs and the optimal settings in which they do so. The clinical trials that are currently in progress and under development will provide the critical foundations for defining the optimal roles of FTIs in patients with AML and other hematologic disorders. The correlative laboratory studies to define the mechanisms by which FTIs alter cellular metabolism and modulate the activities of specific signaling pathways in both normal and malignant marrow precursors are a pivotal part of this effort. What we learn about FTIs in the clinic and the laboratory will apply broadly to the effective and safe application of all signal transduction inhibitors.
Export Options
About this article
Cite this article as:
Karp E. Judith and Lancet E. Jeffrey, Targeting the Process of Farynesylation for Therapy of Hematologic Malignancies, Current Molecular Medicine 2005; 5 (7) . https://dx.doi.org/10.2174/156652405774641052
DOI https://dx.doi.org/10.2174/156652405774641052 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry HCV-Related Transformation and New Therapeutic Strategies: An Update
Current Cancer Therapy Reviews Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes
Current Drug Targets How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments
Current Pharmaceutical Design Pharmacotherapy for Intermittent Claudication: From Consensus-Based to Evidence-Based Treatment
Vascular Disease Prevention (Discontinued) Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management
Cardiovascular & Hematological Agents in Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Anti-cancer Immunotoxins, Challenges, and Approaches
Current Pharmaceutical Design Cytokine Therapy for Cancer
Current Pharmaceutical Design Future Approaches for Treating Hematologic Disease
Current Pharmaceutical Biotechnology Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry Metalloprotein Inhibitors for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Current Pharmaceutical Biotechnology Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets